Two separate studies examined the controversial topic of prescribing statins to high-risk elderly patients who do not already have high cholesterol or cardiovascular disease.

Roche, one of the world’s largest pharmaceutical companies, will gain both oral and injectable assets as a result of this acquisition.

Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.

GLP-1 agonists are often taken as daily or weekly injections. A new delivery system could help make it so those same drugs are only required three times per year. 

The Independent Data Monitoring Committee recommended Bayer stop the trial due to the drug's poor performance compared to apixaban. 

"Although the effectiveness of ADHD medications has been demonstrated ... concerns remain regarding their potential cardiovascular safety," one research explained. 

While the therapy has been successfully tested on animals in the past, this study represents the first time it has been used on humans.

Novo Nordisk shared initial results from the SELECT trial back in August, but now the full analysis—which includes data from more than 17,000 patients—has been published in The New England Journal of Medicine.